Lilly Oncology to Present New Data on Nine of Its Pipeline Molecules at ASCO 2011

INDIANAPOLIS, May 16, 2011 /PRNewswire/ — Data on nine Lilly Oncology molecules
in development will be presented during the 47th Annual Meeting of the American
Society of Clinical Oncology (ASCO) held in Chicago, Ill. from June 3 – 7, 2011.
Lilly Oncology’s pipeline is one of the largest in the industry, with more than
30 molecules in development to treat various types of cancer.

Nearly all of these pipeline molecules are being evaluated for certain
biomarkers or genetic mutations that can help researchers identify which
patients are most likely to respond to these medicines, and as importantly,
which are not.

At ASCO, Lilly will present Phase II data on two fully human IgG1 monoclonal
antibodies: cixutumumab for the treatment of patients with advanced or
metastatic soft tissue sarcoma and Ewing family of tumors; and ramucirumab for
the treatment of locally advanced or metastatic breast cancer. Lilly will also
present data on a Phase I study of LY2127399, a human anti-BAFF antibody for
patients with previously-treated multiple myeloma. Additionally, Lilly will
present data from several studies of enzastaurin, a selective serine-threonine
kinase inhibitor that targets the PKC Beta and PI3/AKT pathways.

“Lilly is very much in alignment with this year’s ASCO conference theme,
‘Patients, Pathways, Progress,’” said Richard Gaynor, M.D., vice president,
product development and medical affairs for Lilly Oncology. “Our extensive
oncology pipeline targets important pathways and specific genetic mutations that
can lead to cancer, which we hope will enable us to come up with better
therapies, more quickly. This is part of our commitment to changing the world of
cancer care,” he added.

Select studies, as well as the times and locations of the data sessions, are
highlighted below.

Cixutumumab (IMC-A12)

— Abstract # 10004: Oral Abstract Session: Monday, June 6, 2011, 4:15 PM -
4:30 PM
o Phase II trial of anti-IGF-IR antibody cixutumumab in patients with
advanced or metastatic soft tissue sarcoma and Ewing family of tumors.
o Author/Speaker: P. Schoffski, D. Adkins, J. Y. Blay, T. Gil, A. D.
Elias, P. Rutkowski, G. K. Pennock, H. Youssoufian, N. J. Zojwalla, R.
Willey, D. O. Grebennik
o Location: E354a

Ramucirumab (IMC-1121B)

— Abstract #TPS151: Trials in Progress Poster Session: Monday, June 6,
2011, 8:00 AM – 12:00 PM
o Randomized phase 2 study of capecitabine with or without ramucirumab
(IMC-1121B) or IMC-18F1 in patients with unresectable, locally
advanced or metastatic breast cancer (mBC) previously treated with
anthracycline and taxane therapy (CP20-0903/NCT01234402).
o Author/Speaker: L. T. Vahdat, K. Miller, J. A. Sparano, H.
Youssoufian, J. D. Schwartz, S. Nanda, W. Wang, L. Abad, A.
Dontabhaktuni, M. D. Rutstein
o Location: Hall A; Poster Board 42E

Anti-BAFF antibody (LY2127399)

— Abstract #8012: Oral Abstract Session: Sunday, June 5, 2011, 11:15 AM -
11:30 AM
o Phase 1 study of LY2127399, a human anti-BAFF antibody, and bortezomib
in patients with previously-treated multiple myeloma
o Author/Speaker: Noopur Raje, Raymond Hohl, Edward Faber, Paul
Richardson, Andres Forero, Gary Schiller, Adam Cohen, Susan Carpenter,
Damien Cronier, Maksim Pashkevich, James Wooldridge, Kenneth Anderson
o Location: E354a

Enzastaurin

— Abstract # 8016: Poster Discussion Session: Saturday, June 4, 2011, 8:00
AM – 12:00 PM
o Randomized Phase II Study of R-CHOP plus enzastaurin versus R-CHOP in
the first-line treatment of patients with intermediate and high-risk
diffuse large B-cell lymphoma (DLBCL) – Preliminary Analysis
o Author/Speaker: John D. Hainsworth, Edward R. Arrowsmith, Michael
McCleod, Luis E. Fayad, Oday Hamid, Lori Davis, Boris Lin
o Location: E450b; Poster Board: 2
— Abstract # 1507: Oral Abstract Session: Monday, June 6, 2011, 5:15 PM -
5:30 PM
o Final Results of a Chemoprevention Trial with Enzastaurin in Former
Smokers
o Author/Speaker: J. Gray, S. Altiok, M. Alexandrow, F. Walsh, J. Chen,
D. Tai, G. Bepler
o Location: S100bc

TGF-beta molecule (LY2157299)

— Abstract # 3011: Poster Discussion Session: Saturday, June 4, 2011, 2:00
PM – 6:00 PM
o First human dose (FHD) study of the oral transforming growth
factor-beta receptor I kinase inhibitor LY2157299 in patients with
treatment-refractory malignant glioma.
o Author/Speaker: Jordi Rodon Ahnert
o Location: S403; Poster Board #1

P-LLY

This press release contains forward-looking statements about the potential of
cixutumumab, ramucirumab, enzastaurin,LY2127399 and LY2157299 and reflects
Lilly’s current beliefs. However, as with any pharmaceutical product, there are
substantial risks and uncertainties in the process of development and
commercialization. There is no guarantee that the products willbecommercially
successful. For further discussion of these and other risks and uncertainties,
see Lilly’s filings with the United States Securities and Exchange Commission.
Lilly undertakes no duty to update forward-looking statements.

SOURCE Eli Lilly and Company